Antibiotic Treatment for Bacterial Respiratory Infections

Upper Respiratory Tract Infections

• The American Academy of Otolaryngology-Head and Neck Surgery recommends amoxicillin-clavulanate (1.75-4 g/250 mg per day) as the first-line treatment for acute bacterial rhinosinusitis in adults with mild disease and no recent antibiotic use, achieving 90-92% predicted clinical efficacy 1, 2
• Amoxicillin-clavulanate remains the reference antibiotic for bacterial sinusitis, with high-dose formulations (4 g/250 mg per day) providing optimal coverage against penicillin-resistant S. pneumoniae, H. influenzae, and M. catarrhalis 1, 3
• Respiratory fluoroquinolones (levofloxacin, moxifloxacin, gatifloxacin) achieve 90-92% predicted clinical efficacy and are recommended for adults with moderate disease or recent antibiotic exposure (within 4-6 weeks) 1, 2, 4
• Ceftriaxone (parenteral, 1-2 g/day for 5 days) achieves 90-92% efficacy and is appropriate for severe cases or when oral therapy fails 1, 2
• Second-generation cephalosporins (cefuroxime axetil) and third-generation cephalosporins (cefpodoxime proxetil, cefdinir) achieve 83-88% efficacy and serve as alternatives for β-lactam-tolerant patients 1, 2, 3

Lower Respiratory Tract Infections

• The European Respiratory Society recommends that immediate antibiotic therapy is NOT recommended for simple acute bronchitis, even with fever present, as most cases are viral 5, 6
• Antibiotics should only be initiated if fever >38°C persists for more than 3 days 5, 6
• For patients with FEV1 >35% and infrequent exacerbations, amoxicillin remains the reference first-line treatment 5, 7, 6
• Treatment is indicated only when at least 2 of 3 Anthonisen criteria are present: increased sputum volume, increased sputum purulence, or increased dyspnea 5, 6
• Amoxicillin-clavulanate is recommended for frequent exacerbations (≥4 per year) or FEV1 <35%, as these patients are more likely to harbor β-lactamase-producing organisms 5, 7
• Respiratory fluoroquinolones (levofloxacin, moxifloxacin) are appropriate for moderate-to-severe disease, achieving high bronchial concentrations and covering resistant pathogens 7
• For patients with severe disease (FEV1 <30%), frequent exacerbations, or prior antibiotic/steroid use, ciprofloxacin (750 mg every 12 hours) is the preferred oral anti-pseudomonal agent 7
• For adults without risk factors, amoxicillin (3 g/day) is the reference treatment for pneumococcal pneumonia 6
• Amoxicillin-clavulanate, parenteral second- or third-generation cephalosporins, and respiratory fluoroquinolones are recommended when risk factors or atypical pathogens are suspected 6
• For children under 3 years, amoxicillin (80-100 mg/kg/day in three divided doses) is the initial treatment of choice 6
• Treatment duration is 7-14 days for adults and 5-8 days for children 6
• Assess therapeutic efficacy within 48-72 hours; do not change antibiotics within this window unless clinical worsening occurs 6